Step by Step


4/17/2018 - Medical Grand Rounds: From Bench to Bedside and Payer to Provider – the Era of Biosimilars





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Evaluate designation of "interchangeable" biosimilars
  • Describe current and emerging biosimilars in the US and around the world
  • Describe similarities and differences between biosimilars and reference biologics

Suggested Additional Reading:

  1. Potential Savings of Biogenerics in the United States, S Miller, J Houts - Express Scripts, 2007
  2. Schieppati, Arrigo, et al. “Why rare diseases are an important medical and social issue.” The Lancet 371.9629 (2008): 2039-2041.
  3. Jorgenson KK et al, UEGW 2016 Late breaking abstract. UEGJ 2016;4(6):805-6
  4. Fiorino G et al, Inflamm Bowel Dis 2017;23:233-43
  5. Danese S et al, J Crohns Colitis 2017;11(1):26-34

Chronis Manolis, RPh — Senior Vice President of Pharmacy Services Chief Pharmacy Officer UPMC Health Plan and UPMC Insurance Services Division
No relationships with industry relevant to the content of this educational activity have been disclosed.
Miguel Regueiro, MD, AGAF, FACG, FACP — Chair, Division of Gastroenterology and Hepatology Cleveland Clinic, Cleveland, OH Professor of Medicine, Lerner College of Medicine, Cleveland, OH
Dr. Regueiro has served as a Faculty, Moderator, and/or Program Organizer for the Medical Education Companies that produced Continuing Medical Education Conferences, Syllabi, and/or Written Materials: Imedex, RMEI, RealCME, Cornerstones, CMEOutfitters, Dr. Regueiro receives research Support from Abbvie, Janssen, Takeda Dr. Reguerio receives Unrestricted Educational Grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Salix, Shire Dr. Reguerio receives Honoraria for Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.